News Akili, Inc.

Equities

AKLI

US00974B1070

End-of-day quote Nasdaq Other stock markets 03:30:00 10/05/2024 am IST			5-day change	1st Jan Change
0.4272 ^USD	-3.87%		+6.37%	-12.30%

30/04	Akili, Inc. Plans to Continue to Pursue Marketing Authorization from the U.S. Food and Drug Administration for Its EndeavorOTC Product	CI
30/04	Akili, Inc. to Reduce Workforce	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Akili Announces Amended Agreement with Shionogi, Shift in Corporate Strategy and Release Date for First Quarter 2024 Financial Results	30/04	BU
Akili, Inc. Plans to Continue to Pursue Marketing Authorization from the U.S. Food and Drug Administration for Its EndeavorOTC Product	30/04	CI
Akili, Inc. to Reduce Workforce	30/04	CI
Akili, Inc. Announces an Amendment to its Strategic Distribution Agreement with Shionogi & Co., Ltd	30/04	CI
Akili, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/03	CI
Akili, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	01/03	CI
Earnings Flash (AKLI) AKILI Posts Q4 Revenue $749,000, vs. Street Est of $0.78M	01/03	MT
Akili Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	01/03	BU
PureTech Founded Entity Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx for Pediatric ADHD Patients in Japan	28/02	AQ
Shionogi & Co., Ltd. - Positive Results from Phase 3 Clinical trial of Digital Therapeutic App SDT-001 and Submission for Marketing Approval in Japan	27/02	AQ
Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx for Pediatric ADHD Patients in Japan	27/02	AQ
Sector Update: Health Care Stocks Ease Late Afternoon	27/02	MT
Akili Shares More Than Double After Submission of ADHD Treatment for Marketing Approval in Japan	27/02	MT
Akili's Japan Partner Submits SDT-001 for Marketing Approval in Japan	26/02	DJ
Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx® for Pediatric ADHD Patients in Japan	26/02	BU
Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's Endeavorrx®? for Pediatric Adhd Patients in Japan	26/02	CI
Akili Announces Release Date for Fourth Quarter and Full Year 2023 Financial Results, Provides Investor Communications and Board and Corporate Governance Updates	22/02	BU
Akili Appoints John Spinale to the Board and Audit Committee	22/02	CI
Akili, Inc. Announces Executive Changes, Effective on January 12, 2024	06/01	CI
Akili, Inc. Announces Resignation of Santosh Shanbhag as Chief Financial Officer, Effective on January 12, 2024	06/01	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Akili, Inc.

Equities

AKLI

US00974B1070

Summary

Filters